From 2,000+ patients · Mounjaro vs Zepbound is already seeing results
Mounjaro vs Zepbound: both are FDA-approved GLP-1 medications for weight loss. Mounjaro (tirzepatide) and Zepbound (tirzepatide) differ in mechanism and clinical efficacy. Weight Method offers both from $199/month with virtual consultations and licensed providers.
Overview
Mounjaro and Zepbound are two separate FDA-approved, once-weekly injectable pens manufactured by Eli Lilly, both containing tirzepatide, a dual GIP and GLP-1 receptor agonist. Mounjaro received FDA approval in 2022 for type 2 diabetes; Zepbound was approved in 2023 for chronic weight management. Both use the same dose range (2.5–15 mg) and identical injection devices — the distinction is purely regulatory and affects how each is prescribed and covered. Weight Method does not dispense or prescribe either brand-name product; our program provides compounded tirzepatide through licensed providers and U.S.-licensed pharmacies. Whether tirzepatide is appropriate for you is a decision made by a licensed provider based on your individual medical profile.
Key Fact
Mounjaro and Zepbound are both tirzepatide products from Eli Lilly. Mounjaro: FDA-approved for type 2 diabetes (May 2022). Zepbound: FDA-approved for chronic weight management (November 2023). Same molecule, same dosing (2.5–15 mg weekly), different FDA-approved indications — and both are different from Weight Method's compounded program.
Source: FDA approval data (Mounjaro; Zepbound)
Mounjaro
Zepbound
| Mounjaro | Zepbound | |
|---|---|---|
| Manufacturer | Eli Lilly | Eli Lilly |
| Active Ingredient | tirzepatide | tirzepatide |
| FDA Indication | Type 2 diabetes | Chronic weight management |
| FDA Approval | 2022 | 2023 |
| Formulation | Injectable pen | Injectable pen |
| Frequency | Once weekly | Once weekly |
| Available Doses | 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg | 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg |
| Avg. Weight Loss | 15-21% | 20-25% |
| Our Price | $329/mo | $329/mo |
Key Differences
Mounjaro and Zepbound contain the same molecule at the same doses; the difference is the FDA-approved indication (type 2 diabetes vs. chronic weight management) and how each is covered by insurers. The mechanism class — dual GIP/GLP-1 receptor agonist — is identical. Which medication and indication is clinically appropriate for any individual is determined by a licensed provider based on that person's medical history. Weight Method's program offers compounded tirzepatide at $329/mo, a flat all-inclusive monthly rate.
Verdict
Mounjaro and Zepbound are distinct FDA-approved branded products from Eli Lilly with different approved uses; neither is what Weight Method dispenses. The right option for an individual — and whether tirzepatide is appropriate at all — depends on that person's medical profile and is determined by a licensed provider. Weight Method provides compounded tirzepatide at $329/mo through a streamlined online consultation.
Your Treatment Options
Compounded GLP-1 medications dispensed by U.S.-licensed 503A pharmacies.
